Free Trial
OTCMKTS:IPSEY

Ipsen (IPSEY) Stock Price, News & Analysis

Ipsen logo
$28.33 +0.43 (+1.52%)
As of 11:39 AM Eastern

About Ipsen Stock (OTCMKTS:IPSEY)

Key Stats

Today's Range
$28.33
$28.33
50-Day Range
$25.77
$30.79
52-Week Range
$25.11
$34.06
Volume
849 shs
Average Volume
6,043 shs
Market Capitalization
$9.50 billion
P/E Ratio
N/A
Dividend Yield
0.74%
Price Target
N/A
Consensus Rating
Buy

Company Overview

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Receive IPSEY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter.

IPSEY Stock News Headlines

Ipsen S.A. (IPSEY) Q1 2025 Earnings Call Transcript
🥾⛏️👷‍♂️ What I Learned From Numerous Mine Visits...
Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining stocks like most gold analyst CFAs, I decided to visit every significant gold mine I could. 10+ site visits later, I've confirmed my theory... That the most profitable mines share three specific characteristics. When you find all three together, the returns can be staggering.
RBC Capital Sticks to Its Buy Rating for Ipsen (0MH6)
See More Headlines

IPSEY Stock Analysis - Frequently Asked Questions

Ipsen's stock was trading at $28.97 at the start of the year. Since then, IPSEY shares have decreased by 2.2% and is now trading at $28.3250.
View the best growth stocks for 2025 here
.

Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
4/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
OTCMKTS:IPSEY
CIK
N/A
Employees
5,325
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.87 billion
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$9.35 billion
Optionable
Not Optionable
Beta
0.80

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (OTCMKTS:IPSEY) was last updated on 4/28/2025 by MarketBeat.com Staff
From Our Partners